Kimberly Hartig

Statistics

Publications

Citations

445

H-Index

Active since

2010

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Hackensack University Medical Center

Kimberly Hartig is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, lymphoma chemotherapy, and hematologic malignancy therapy.

Publications per year

2010–2021

Publications

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

Michael Wang, Luis Fayad, Nicolaus A. Wagner‐Bartak et al. · The Lancet Oncology · 2012 · 297 citations

Medicine, Oncology, Pharmacotherapy +16

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma

Shaojun Zhang, Changying Jiang, Guangchun Han et al. · Nature Communications · 2021 · 67 citations · Full text

Medicine, Cancer Biology, Oncology +17

Phase I trial of bortezomib in combination with rituximab‐HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma

Jorge Romaguera, Luis Fayad, Peter McLaughlin et al. · British Journal of Haematology · 2010 · 48 citations

Medicine, Pharmacology, Pharmacotherapy +15

Chemotherapy-Free Induction with Ibrutinib-Rituximab Followed By Shortened Cycles of Chemo-Immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: A Phase II Clinical Trial

Michael Wang, Hun Ju Lee, Selvi Thirumurthi et al. · Blood · 2016 · 19 citations

Medicine, Immunology, Oncology +12

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma

Jorge Romaguera, Michael Wang, Lei Feng et al. · Cancer · 2018 · 14 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

1–5 of 5